Orbimed Capital LLC, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 1,260,164 shares at $12.94 ($16.6M) on 2024-08-22, disclosed to the SEC on 2024-08-23.
Open-market sale of $16.6M SPRY by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.52 | 394,400 | $5.3M | 32.2% |
| 2 | $14.61 | 13,300 | $194K | 1.2% |
| 3 | $12.94 | 391,482 | $5.1M | 30.6% |
| 4 | $12.94 | 391,482 | $5.1M | 30.6% |
| 5 | $13.03 | 69,500 | $906K | 5.5% |
| Total | $13.14 avg | 1,260,164 |
| $16.6M |
| 100% |
| Filing → |
| ARQT | SELL | 2022-04-08 | $25.4M | — | Filing → |
| RPTX | SELL | 2021-08-30 | $993K | — | Filing → |
| RPTX | SELL | 2021-08-25 | $1.2M | — | Filing → |